All articles tagged with #q4 2025
The Commerce Department revised U.S. fourth-quarter GDP growth down to 0.5%, signaling a softer end to the year and potentially influencing the 2026 outlook and Federal Reserve policy as spending and investment cooled.
Counterpoint Research ranks Apple’s iPhone 17 Pro Max, iPhone 17, and iPhone 17 Pro as the world’s top-selling smartphones for Q4 2025, with the Pro Max capturing about 5% of global smartphone sales; Samsung’s Galaxy lineup also performed well but couldn’t surpass Apple’s Q4 2025 dominance.
BEA’s third estimate shows U.S. real GDP rising 0.5% at an annual rate in Q4 2025, revised down 0.2 percentage point from the second estimate due mainly to weaker investment. Growth was supported by higher consumer spending and investment but weighed down by declines in government spending and exports, with imports also subtracted. Private services-producing activity rose 2.3%, while government (-7.8%) and private goods-producing (-1.8%) fell; wholesale trade, information, and health care and social assistance were key contributors. Real final sales to private domestic purchasers rose 1.8%; real gross output fell 0.5%. Corporate profits climbed about $247 billion in Q4. For 2025 overall, real GDP rose 2.1% and personal income grew 4.9%, with gains across states; Hawaii benefited from Maui wildfire settlement transfers, while DC lagged. The release notes that the October 2025 government shutdown shaved roughly 1.0 percentage point from Q4 growth and that October CPI data were imputed. Next BEA update is April 30, 2026.
Real GDP rose at a 0.7% annual rate in Q4 2025, down from 4.4% in Q3, helped by consumer spending and investment but dragged by government spending and exports; imports fell, and 2025 real GDP increased 2.1%. The October government shutdown and missing CPI data affected the release, with BEA’s next update scheduled for April 9, 2026 and data tables available online.
Berkshire Hathaway reported Q4 2025 operating earnings of $10.2B, down about 29% from a year earlier, with insurance underwriting profits down 54% to $1.56B and insurance investment income down ~25% to $3.1B. This was Buffett’s final quarter as CEO before Greg Abel begins 2026. For 2025, operating earnings totaled $44.49B and overall earnings $66.97B, pressured by a $4.5B impairment from Kraft Heinz and Occidental; investment gains helped but overall earnings still fell. Berkshire did not buy back shares and its cash hoard eased to $373.3B, while its stock rose ~10% in 2025, lagging the S&P 500.}
Flutter Entertainment reported a Q4 2025 miss across most metrics, with revenue of $4.74B (vs. $4.97B expected), adjusted EPS of $1.74 (vs. $1.95), and EBITDA of $832M (vs. $893M). Revenue rose 25% year over year, but 2026 revenue guidance of $17.75B–$19.05B came in below consensus. CEO Peter Jackson cited tougher bettor conditions and said prediction markets could spur legalization, while there was no evidence of sportsbook cannibalization. Shares fell about 7% after hours.
MARA Holdings announced preliminary unaudited Q4 2025 and full-year 2025 results, posted a shareholder letter, and scheduled an investor webcast/conference call for February 26, 2026 to discuss the figures.
HBO Max ended the year with 131.6 million subscribers and helped streaming revenue rise in Q4, while Warner Bros. Discovery posted a 6% drop in quarterly revenue to $9.46 billion and a 19% fall in adjusted EBITDA, amid NBA ad-headwinds and ongoing merger drama with Paramount and Netflix; streaming profitability improved, and the company pressed ahead with international expansion and a potential spin-off of Discovery Global.
Lowe's reported $20.58 billion in Q4 2025 sales and net earnings of $999 million ($1.78 per share), with adjusted diluted EPS of $1.98 after excluding $149 million in pre-tax costs tied to the Foundation Building Materials and Artisan Design Group acquisitions. For the full year, net earnings were $6.654 billion and the company provided a 2026 outlook of $92–$94 billion in sales, flat-to up 2% in comparable sales, and adjusted diluted EPS of $12.25–$12.75 (GAAP diluted EPS about $11.75–$12.25), with operating margin 11.2%–11.4%, and capex around $2.5 billion. The firm highlighted growth in Pro, online, and home services, paid $673 million in dividends in Q4 and returned about $2.6 billion to shareholders in 2025, and remains optimistic on share gains amid housing-market headwinds through productivity initiatives.
Hims & Hers Health reported mixed Q4 and full-year 2025 results: EPS of $0.08 beat consensus of $0.04 but down 27% year-over-year, while Q4 revenue rose 28% to $617.8 million but missed estimates of $619.2 million. U.S. revenue climbed 17% to $554.15 million, with international revenue up about 825% as it expands globally. Monthly revenue per average subscriber rose 11% to $83. For 2026, the company guided Q1 revenue of $600–$625 million and adjusted EBITDA of $35–$55 million, with full-year revenue of $2.7–$2.9 billion, aiming for longer-term targets of $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA by 2030; stock moved lower in after-hours trading amid the mixed results.
US GDP rose at a 1.4% annualized rate in Q4 2025, undershooting economists’ expectations of about 3%, as disruptions from the government shutdown and softer consumer spending weighed on growth. The CBO estimated the shutdown shaved roughly 1.5 percentage points from Q4 GDP, with most lost output expected to be recovered. AI-related investment and tax cuts are seen as supports for activity later in the year, even as the economy remains uneven and inflation pressures persist.
Asian stock markets were muted in holiday-thinned trade as Japan’s Q4 GDP undershot expectations (0.2% year-on-year vs 1.6%), with weak capex and exports weighing on sentiment, while Hong Kong edged higher and Australia rose modestly amid a cautious regional tone as U.S. markets remained closed for the holiday.
CVS Health beat Q4 estimates with adjusted EPS of $1.09 and revenue of $105.69 billion, and reaffirmed its 2026 guidance of $7.00–$7.20 per share and at least $400 billion in revenue. Management cited headwinds from exiting ACA exchanges and lower drug prices under new pricing deals, while growth is expected from Caremark and improving Aetna margins, Oak Street Health, and the Rite Aid prescription integration.
Pfizer is set to report Q4 earnings before the open, with expectations for EPS of $0.57 on about $16.85 billion in revenue, continuing its streak of beating earnings in 15 of the last 16 quarters. Yet upside looks limited given 2026 guidance, so focus may shift to new drug data (VESPER-3 obesity study, Lyme vaccine, prostate cancer treatment, NSCLC therapy) and potential US pricing pressure from Medicare negotiations starting in 2028. Options imply roughly a 3.6% move post-earnings, and Wall Street holds a Moderate Buy with a around $28.5 average target (AI target about $29).
Meta Platforms gained about 7–8% pre-market after a solid Q4 beat, with Jefferies noting META trades at roughly 21x forward earnings versus Alphabet’s ~28x—a gap the firm says is wider than historical norms and implies a valuation discount. META posted $8.88 per share on $59.89B in revenue; it also guided capex up to $135B to power AI, a spend that could compress margins by around 5% this year, though cost controls and a leaner metaverse push are positives. Five-star analyst Brent Thill remains bullish with a $910 price target (≈35% upside), and the street-wide Strong Buy rating still points to meaningful upside, with an average target around $830 (~24% upside).